Home About Contact Add Activities Provider Login Mobile Apps

i3 Health

	Best Practices in Nursing Management of Chemotherapy-Induced Peripheral Neuropathy STATEMENT OF NEED Chemotherapy-induced peripheral neuropathy (CIPN) is a complication of cancer treatment that may impair quality of life and lead to treatment dose reductions or discontinuation in severe cases. In one study of 123 patients receiving taxane therapy for breast cancer, 17% required dose reductions because of CIPN (Bhatnagar et al, 2014). Whereas in some patients the symptoms of... i3 Health
	Clinical Updates and Expert Guidance in Prostate Cancer STATEMENT OF NEED Prostate cancer is the most common tumor type affecting men in the United States, with an estimated 174,650 new cases reported each year. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from cast... i3 Health
	Current Challenges and New Opportunities in Hematopoietic Stem Cell Transplant STATEMENT OF NEED Hematopoietic stem cell transplant is a potentially curative therapy for patients with hematologic malignancies. There are 2 primary types of HSCT: autologous, where the cells are taken from the patient, and allogeneic, where the cells come from a matched sibling donor or an unrelated donor. Advances in HSCT include the introduction of reduced-intensity conditioning regimens... i3 Health
	Current Standards and Best Practices in the Management of Tumor Lysis Syndrome STATEMENT OF NEED Tumor lysis syndrome (TLS) is a rare, potentially life-threatening oncologic emergency typically associated with chemotherapy-induced tumor cell death in which potassium, phosphate, and nucleic acids are released into the bloodstream. This release of intracellular materials results in severe metabolic abnormalities such as hyperuricemia and hyperphosphatemia, which may cause... i3 Health
	Enhancing Treatment Experiences in Castration-Resistant Prostate Cancer: The Nurse's View STATEMENT OF NEED Prostate cancer is the most common tumor type affecting men in the United States, with an estimated 174,650 new cases reported each year. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from cast... i3 Health
	Exploring Novel Treatment Strategies for Metastatic Colorectal Cancer STATEMENT OF NEED Colorectal cancer (CRC) is the third leading cause of cancer death among men and women in the United States. An estimated 145,600 new cases are diagnosed annually and 51,020 people die of the disease. When detected and treated early at a localized stage, the 5-year survival rate is 90%. However, because CRC initially exhibits no symptoms and the use of routine screening is s... i3 Health
	Management of Cancer Pain: Current Guidelines STATEMENT OF NEED Cancer patients often experience a range of symptoms that negatively impact their quality of life. Among the most debilitating is pain. Despite efforts to increase awareness, cancer pain is still underdiagnosed and undertreated and patients do not obtain complete relief. Although numerous management guidelines for cancer pain have been developed, most health care practitione... i3 Health
	Management of Venous Thromboembolism in Ambulatory Patients With Cancer STATEMENT OF NEED Venous thromboembolism (VTE) is a common and potentially life-threatening complication in patients with cancer. There are two main types of VTE: deep vein thrombosis (DVT) and pulmonary embolus (PE), which can cause right heart failure, cardiopulmonary collapse, and death (Ozaki & Bartholomew, 2012). Patients who develop PE require hospitalization, increased oxygen requireme... i3 Health
	Management of Venous Thromboembolism in Hospitalized Patients With Cancer STATEMENT OF NEED Venous thromboembolism (VTE), which consists primarily of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a life-threatening complication in hospitalized patients with cancer, and is associated with a 2- to 6-fold increase in likelihood of death (NCCN, 2016). The mainstay of treatment is anticoagulation; however, since cancer patients with VTE have higher rates of... i3 Health
	Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care STATEMENT OF NEED Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites (eg, cortical bone). Approximately 32,270 new cases of MM are diagnosed in the United States annually and 12,830 people die of the disease. Although the tumor cells remain primarily within the bone marrow, they can cause a number of c... i3 Health
	New Clinical Perspectives in the Management of Myelofibrosis STATEMENT OF NEED Myelofibrosis is a rare type of myeloproliferative neoplasm—a heterogenous group of hematopoietic disorders—that affects approximately 13,000 individuals in the United States. As symptoms do not typically manifest in early stages, patients with myelofibrosis often present with advanced disease. The presence of comorbidities precludes most from allogeneic stem cell transp... i3 Health
	New Thinking, New Strategies in Advanced Urothelial Carcinoma STATEMENT OF NEED Bladder cancer is the sixth most common malignancy among adults in the United States. Approximately 80,470 new cases are diagnosed annually and 17,670 people die of the disease. More than 90% of patients with bladder cancer have the urothelial carcinoma subtype, which has a high rate of recurrence whether it is low or high grade. Approximately half of all bladder cancers are... i3 Health
	New Thinking, New Strategies in the Treatment of Advanced NSCLC Without Driver Mutations STATEMENT OF NEED Of the estimated 228,150 patients diagnosed with lung cancer in the United States each year, 84% have non-small cell lung cancer (NSCLC). Most patients with NSCLC present with advanced disease, which is highly resistant to chemotherapy. The 5-year survival rates remain dismal (18%). Recently, the use of tumor histology in determining optimal treatment strategies and relevant... i3 Health
	Nursing Management of Bone Health in Patients With Cancer STATEMENT OF NEED Many tumors, such as prostate, breast, lung, and multiple myeloma, affect bone health. Once cancer spreads to the skeletal system, the risk for pain, fractures, hypercalcemia, and nerve compression increases considerably. Several studies have shown that the use of antiresorptive agents such as bisphosphonates and monoclonal antibodies can reduce the morbidity of skeletal com... i3 Health
	Nursing Management of Myelofibrosis: Controlling Symptoms and Optimizing Patient Quality of Life STATEMENT OF NEED Myeloproliferative neoplasms are a heterogeneous group of hematopoietic disorders that includes myelofibrosis, polycythemia vera (PV), and essential thrombocythemia (ET). These malignancies affect approximately 13,000, 134,000, and 148,000 individuals in the United States, respectively. As symptoms do not typically manifest in early stages, patients with MPNs often present w... i3 Health
	Optimizing Personalized Care Plans for Patients With Advanced Non-Small Cell Lung Cancer STATEMENT OF NEED An estimated 228,150 new cases of lung cancer are reported in the United States annually, and 142,670 people die of the disease. The major subtypes are non-small cell (84%) and small cell (13%). Most patients with lung cancer are diagnosed at a locally advanced or metastatic stage, making systemic therapy the cornerstone of management. Although 70% of patients receiving fi... i3 Health
	Optimizing the Clinical Outcomes of Patients With Immune Thrombocytopenia STATEMENT OF NEED Immune thrombocytopenia (ITP) is a heterogeneous disorder with variable clinical features that range from asymptomatic thrombocytopenia to bothersome bruising to life-threatening intracranial hemorrhage. The lack of specific diagnostic criteria remains an important unmet need. Bleeding events are the most common clinical manifestation of ITP but are unpredictable with curren... i3 Health
	Prevention of Medical Errors in Nursing Practice STATEMENT OF NEED Medical errors are among the most common health-threatening mistakes that affect patient care, accounting for as many as 250,000 deaths per year in the United States (Makary & Daniel, 2016). Medical errors are considered a global problem, complicating a patient’s primary condition for which they needed medical attention. These errors can lead to adverse outcomes such as incr... i3 Health
	Virtual Tumor Board: Diagnosis and Management of Myelodysplastic Syndromes STATEMENT OF NEED Myelodysplastic syndromes (MDS) are a group of heterogeneous hematopoietic disorders derived from an abnormal multipotent progenitor cell, characterized by ineffective hematopoiesis, bone marrow failure, and peripheral blood cytopenias. Survival in MDS ranges from a median of 5.3 years in lower-risk patients to as little as 0.8 years in higher-risk patients. Mortality is usu... i3 Health

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.